OHR Pharmaceutical Inc.

Ohr Pharmaceutical to Announce Third Quarter 2016 Financial Results on August 9

Download PDF

NEW YORK, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the third quarter ended June 30, 2016 after the market close on Tuesday, August 9, 2016.  The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.

Conference Call & Webcast
Tuesday, August 9th at 5:00pm Eastern Time
 
Domestic: 877-407-0789
International: 201-689-8562
Conference ID: 13642605
Webcast: http://public.viavid.com/index.php?id=120651
 
Replays – Available through August 16, 2016
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 13642605


About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in a Phase 3 clinical program for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.  Additional information on the company may be found at www.ohrpharmaceutical.com.

Contact:
Ohr Pharmaceutical Inc.
Investor Relations  
888-388-2327   
ir@ohrpharmaceutical.com

LifeSci Advisors, LLC
Michael Wood
646-597-6983
mwood@lifesciadvisors.com

Primary Logo

Source: Ohr Pharmaceutical, Inc.